482 related articles for article (PubMed ID: 24170665)
1. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.
Monge-Maillo B; López-Vélez R
Drugs; 2013 Nov; 73(17):1889-920. PubMed ID: 24170665
[TBL] [Abstract][Full Text] [Related]
2. Interventions for Old World cutaneous leishmaniasis.
Heras-Mosteiro J; Monge-Maillo B; Pinart M; Lopez Pereira P; Reveiz L; Garcia-Carrasco E; Campuzano Cuadrado P; Royuela A; Mendez Roman I; López-Vélez R
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD005067. PubMed ID: 29149474
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review.
van Griensven J; Gadisa E; Aseffa A; Hailu A; Beshah AM; Diro E
PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004495. PubMed ID: 26938448
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany].
Boecken G; Sunderkötter C; Bogdan C; Weitzel T; Fischer M; Müller A; Löbermann M; Anders G; von Stebut E; Schunk M; Burchard G; Grobusch M; Bialek R; Harms-Zwingenberger G; Fleischer B; Pietras M; Faulde M; Erkens K; ; ;
J Dtsch Dermatol Ges; 2011 Nov; 9 Suppl 8():1-51. PubMed ID: 22050890
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
6. Interventions for American cutaneous and mucocutaneous leishmaniasis.
González U; Pinart M; Rengifo-Pardo M; Macaya A; Alvar J; Tweed JA
Cochrane Database Syst Rev; 2009 Apr; (2):CD004834. PubMed ID: 19370612
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniasis: recognition and management with a focus on the immunocompromised patient.
Choi CM; Lerner EA
Am J Clin Dermatol; 2002; 3(2):91-105. PubMed ID: 11893221
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
[TBL] [Abstract][Full Text] [Related]
9. Old world cutaneous leishmaniasis in Iran: clinical variants and treatments.
Firooz A; Mortazavi H; Khamesipour A; Ghiasi M; Abedini R; Balighi K; Esmaili N; Nassiri-Kashani M; Eskandari SE; Mohebali M; Mir Amin Mohammadi A; Dowlati Y
J Dermatolog Treat; 2021 Nov; 32(7):673-683. PubMed ID: 31869258
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and treatment response of cutaneous leishmaniasis in North-West Ethiopia.
Fikre H; Mohammed R; Atinafu S; van Griensven J; Diro E
Trop Med Int Health; 2017 Oct; 22(10):1293-1301. PubMed ID: 28712122
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
Oliveira LF; Schubach AO; Martins MM; Passos SL; Oliveira RV; Marzochi MC; Andrade CA
Acta Trop; 2011 May; 118(2):87-96. PubMed ID: 21420925
[TBL] [Abstract][Full Text] [Related]
12. Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.
Basile G; Cristofaro G; Locatello LG; Vellere I; Piccica M; Bresci S; Maggiore G; Gallo O; Novelli A; Di Muccio T; Gramiccia M; Gradoni L; Gaiera G; Bartoloni A; Zammarchi L
Int J Infect Dis; 2020 Aug; 97():204-207. PubMed ID: 32505874
[TBL] [Abstract][Full Text] [Related]
13. Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report.
Mushtaq S; Dogra D; Dogra N
Dermatol Ther; 2016 Nov; 29(6):398-405. PubMed ID: 27477764
[TBL] [Abstract][Full Text] [Related]
14. Eligibility for Local Therapies in Adolescents and Adults with Cutaneous Leishmaniasis from Southwestern Colombia: A Cross-Sectional Study.
Uribe-Restrepo AF; Prieto MD; Cossio A; Desai MM; Castro MDM
Am J Trop Med Hyg; 2019 Feb; 100(2):306-310. PubMed ID: 30628567
[TBL] [Abstract][Full Text] [Related]
15. [Management of cutaneous leishmaniasis in adults and children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2005 Nov; 65(5):487-95. PubMed ID: 16465821
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns.
Padovese V; Terranova M; Toma L; Barnabas GA; Morrone A
Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):707-11. PubMed ID: 19356780
[TBL] [Abstract][Full Text] [Related]
17. A Therapeutic update on Cutaneous leishmaniasis.
Bari AU; Rahman SB
J Coll Physicians Surg Pak; 2003 Aug; 13(8):471-6. PubMed ID: 12921689
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study.
Rodríguez Galvis MC; Pérez Franco JE; Casas Vargas MY; Ordoñez Rubiano MF
Am J Trop Med Hyg; 2020 Feb; 102(2):274-279. PubMed ID: 31820708
[TBL] [Abstract][Full Text] [Related]
19. New world cutaneous leishmaniasis in travellers.
Schwartz E; Hatz C; Blum J
Lancet Infect Dis; 2006 Jun; 6(6):342-9. PubMed ID: 16728320
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management.
Ameen M
Expert Opin Pharmacother; 2010 Mar; 11(4):557-69. PubMed ID: 20163267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
